| | Identification | Back Directory |  | [Name] 
 CHPG
 |  | [CAS] 
 170846-74-9
 |  | [Synonyms] 
 CHPG
 (RS)-2-CHLORO-5-HYDROXYPHENYLGLYCINE
 α-amino-2-chloro-5-hydroxybenzeneacetic acid
 Benzeneacetic acid, α-amino-2-chloro-5-hydroxy-
 (RS)-2-chloro-5-hydroxyphenylglycine α-amino-2-chloro-5-hydroxybenzeneacetic acid
 α-Amino-2-chloro-5-hydroxybenzeneacetic  acid,  (RS)-2-Chloro-5-hydroxyphenylglycine
 |  | [Molecular Formula] 
 C8H8ClNO3
 |  | [MDL Number] 
 MFCD01321059
 |  | [MOL File] 
 170846-74-9.mol
 |  | [Molecular Weight] 
 201.61
 | 
 | Hazard Information | Back Directory |  | [Description] 
 (R,S)-CHPG is a potent and selective agonist at metabotropic glutamate receptor 5 (mGluR5). In CHO cells, it had an EC50 of 750 μM for calcium mobilization in mGluR5a-expressing cells but was inactive in mGluR1a-expressing cells. In transfected HEK293 cells, (R,S)-CHPG bound mGluR1a and mGluR5a (Kis = 0.9 and 3.9 μM, respectively) but not ionotropic glutamate receptors. It reduced oxidative stress and inflammatory markers in cultured BV-2 microglial cells. In mouse models of traumatic brain injury, it reduced lesion volume, improved sensorimotor deficits in the beam walk test, and improved spatial memory in the Morris water maze.
 |  | [Uses] 
 CHPG is a selective mGluR-5 agonist.
 |  | [Biological Activity] 
 A  selective  mGlu  5 metabotropic  glutamate  receptor  agonist,  completely  inactive  at  mGlu  1a receptors  expressed  in  CHO  cells.  Active in  vivo  .
 |  | [in vitro] 
 (r,s)-2-chloro-5-hydroxyphenylglycine [chpg] selectively activated mglu5a receptors with no activation of mglu1a receptors. this selective mglu5 receptor agonist also enhances nmda-induced depolarizations in rat hippocampalslices. chpg may be used to study the role of mglu5 receptors in the cns [1].
 |  | [in vivo] 
 to compare the effects of treatment with the newly developed selective mglur5 antagonist mpep and the selective mglur5 agonist chpg in a rat intraluminal filament model of temporary middle cerebral artery occlusion (mcao), rats, after induction of ischemia for 2 h, were administered mpep or chpg (i.c.v.) beginning 15 or 135 min. measured after either 22 or 70 h of reperfusion measured infarct size, and quantified neurological function at 2, 24, 48 and 72 h. 24 h infarct volumes after treatment with mpep or chpg at 15 min were reduced by 61 and 44%, respectively. the neuroprotective effects were dose-dependent. the neuroprotective effects were eliminated by delaying mpep treatment until 135 min. in other studies, with early mpep treatment (15 min) at optimal doses, infarct volume was reduced by 44% at 72 h, being correlated with significant neurological recovery [2].
 |  | [storage] 
 +4°C (desiccate)
 |  | [References] 
 [1] doherty aj, palmer mj, henley jm, collingridge gl, jane de.  (rs)-2-chloro-5-hydroxyphenylglycine (chpg) activates mglu5, but no mglu1, receptors expressed in cho cells and potentiates nmda responses in the hippocampus. neuropharmacology. 1997 feb;36(2):265-7.
 [2].  bao wl, williams aj, faden ai, tortella fc. selective mglur5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia. brain res. 2001 dec 20;922(2):173-9.
 | 
 | 
                    
                        
                            | Company Name: | BOC Sciences |  
                            | Tel: | 1-631-485-4226; 16314854226 |  
                            | Website: | https://www.bocsci.com |  
                    
                        
                            | Company Name: | Energy Chemical |  
                            | Tel: | 021-58432009 400-005-6266 |  
                            | Website: | http://www.energy-chemical.com |  
                    
                        
                            | Company Name: | Wuhan Topule |  
                            | Tel: | +86-02787215551 +86-19945035818 |  
                            | Website: | http://www.topule.com/ |  |